Share-Based Compensation (Tables)

12 Months Ended

Jun. 30, 2012

Schedule Of Fair Value Of Stock Option Grant Weighted-Average Assumptions

	2012	2011	2010
Risk-free interest rate	1.0%	1.8%	1.8%
Expected dividend yield	0%	0%	0%
Expected lives (in years)	4.2 - 4.6	4.2 - 4.4	4.1 - 4.3
Expected volatility	44%	43%	45%

Schedule Of Share-Based Compensation Arrangement By Share Based Payment Award Options Outstanding

	2012					2011					2010
	Number of shares			Weighted average exercise price		Number of shares			Weighted average exercise price		Number of shares			Weighted average exercise price
Options outstanding at beginning of year		14,453,913		$	18.22		14,116,938		$	18.03		14,372,056		$	15.66
Options granted		3,188,160			20.42		3,102,440			17.63		2,728,080			26.58
Less:
Options exercised		(1,852,245	)		11.94		(1,876,303	)		12.06		(1,968,450	)		10.28
Options canceled or expired		(556,547	)		21.48		(889,162	)		26.09		(1,014,748	)		22.53
Options outstanding at end of year		15,233,281			19.32		14,453,913			18.22		14,116,938			18.03
Options exercisable at end of year		8,397,678			18.01		7,794,782			15.53		7,741,122			13.93
Options vested and expected to vest		14,514,637			19.28		13,662,687			18.10		12,830,455			17.46
Weighted average fair value of options granted during the year					7.47					6.61					10.00

Schedule Of Share-Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Option Exercisable

Range of exercise prices	Options outstanding						Options exercisable
	Number outstanding at June 30, 2012		Weighted average remaining contractual life (years)		Weighted average exercise price		Number exercisable at June 30, 2012		Weighted average exercise price
$ 3.80 - 16.53		4,808,613		5.12	$	11.84		3,827,996	$	10.68
16.99 - 19.47		4,555,044		8.26		18.76		1,173,622		18.03
19.70 - 30.12		4,836,130		7.35		24.94		2,863,701		25.51
30.34 - 30.56		1,033,494		7.14		30.34		532,359		30.34
		15,233,281		6.91				8,397,678		18.01

Schedule Of Share-Based Compensation Recognized In Statement Of Operations

	Years Ended June 30,
(In thousands)	2012		2011		2010
Cost of molecular diagnostic testing	$	1,158	$	1,200	$	1,005
Cost of companion diagnostic services		85		—		—
Research and development expense		3,350		3,902		3,689
Selling, general, and administrative expense		21,682		19,986		18,082
Total share-based compensation expense		26,275		25,088		22,776

Schedule Of Unrecognized Share-Based Compensation Cost

(In thousands)	As of June 30, 2012
Unrecognized share-based compensation cost	$	35,224
Aggregate intrinsic value of options outstanding	$	82,878
Aggregate intrinsic value of options fully vested	$	58,256

Schedule Of Intrinsic Value Of Options Exercised

	Years Ended June 30,
(In thousands)	2012		2011		2010
Total intrinsic value of options exercised	$	21,575	$	20,215	$	26,797

Schedule Of Shares Purchased And Compensation Expenses

	Years Ended June 30,
(In thousands)	2012		2011		2010
Shares purchased under the Plan		161		145		121
Plan compensation expense	$	892	$	807	$	823

Employee Stock Purchase Plan [Member]

Schedule Of Fair Value Of Stock Option Grant Weighted-Average Assumptions

	2012			2011			2010
Risk-free interest rate		0.1	%		0.1	%		0.2	%
Expected dividend yield		0	%		0	%		0	%
Expected lives (in years)		0.5			0.5			0.5
Expected volatility		30	%		35	%		50	%